Alpha Teknova, Inc. filings document the company’s operating results, governance matters and public-company disclosures as a producer of critical reagents for life-sciences customers. Form 8-K reports furnish quarterly and annual earnings releases, revenue by Lab Essentials and Clinical Solutions, guidance, cash metrics, borrowings and related exhibits.
Proxy and current-report filings cover director elections, auditor ratification, annual meeting vote results, board and stockholder procedures, and amendments to the company’s Code of Business Conduct and Ethics. The filing record also identifies Teknova’s common-stock issuer status, emerging growth company disclosure and corporate-governance framework.
Alpha Teknova, Inc. (TKNO) filed a Form 4 on 06/25/2025 reporting an equity award to its President & CEO and Director, Stephen Gunstream.
• On 02/14/2025 Gunstream received a non-qualified stock option covering 393,663 shares of common stock at an exercise price of $8.28 per share. The award was coded “A,” indicating an acquisition by grant, and carries an exercise period that expires on 02/14/2035.
• The option vests in 48 equal monthly instalments beginning on the grant date, providing full vesting after four years. No price was paid for the option itself (reported as $0.00), consistent with standard incentive-based grants.
• After the transaction Gunstream directly holds 393,663 derivative securities and reported no indirect holdings. The filing shows no acquisition or disposition of non-derivative (actual share) securities.
This routine incentive grant strengthens management–shareholder alignment through performance-linked compensation, while also adding a potential share overhang equivalent to the optioned amount once exercised.
Alpha Teknova, Inc. (TKNO) – Form 4 insider transaction filed 06/25/2025
Director Martha J. Demski reported the acquisition of 54,300 shares of TKNO common stock on 06/17/2025. The transaction is coded “A,” indicating the shares were awarded, not purchased on the open market. According to the footnote, the shares represent restricted stock units (RSUs) that will vest in full on the first anniversary of the grant date.
Following the award, Demski’s direct beneficial ownership increased to 74,300 shares. No derivative securities were reported in Table II, and the filing does not disclose any sale or disposition of shares.
The filing was signed by attorney-in-fact Damon A. Terrill on 06/25/2025.
- Insider role: Director (not an officer or 10% owner)
- Total shares after grant: 74,300 (direct)
- Grant terms: 54,300 RSUs; vest 100% on 06/17/2026
- Cost basis: $0.00, reflecting equity compensation
This Form 4 reflects routine director compensation via RSUs. While the additional equity strengthens alignment with shareholders, it does not signal an open-market confidence purchase.
Alpha Teknova, Inc. (Nasdaq: TKNO) filed a Form 8-K reporting the results of its 2025 Annual Meeting of Stockholders held on June 17, 2025. A strong quorum of 88.62% of outstanding shares (47,356,521) was present in person or by proxy.
Proposal 1 – Election of Class I Directors: Martha J. Demski and Alexander Herzick were elected to serve until the 2028 Annual Meeting. Each received more than 42.5 million “for” votes, with fewer than 1 million votes withheld and 4.0 million broker non-votes.
Proposal 2 – Auditor Ratification: Grant Thornton LLP was ratified as independent auditor for fiscal 2025 with 47,336,767 “for” votes, representing virtually unanimous support (99.96% of votes cast).
No other matters were brought before shareholders, and the filing contained no financial performance updates or strategic disclosures. These results reflect routine corporate-governance actions with broad shareholder endorsement.